Showing results (121-130 of 140) with videos related to

Sort By:
Pageof 14
Frontiers in Immunology|April 29, 2024
Exploring aryl hydrocarbon receptor expression and distribution in the tumor microenvironment, with a focus on immune cells, in various solid cancer typesDong Kwon Kim, Chai Young Lee, Yu Jin Han, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2017
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 RearrangementSun Min Lim, Hye Ryun Kim, Jong-Seok Lee, et al.
Cancers|October 28, 2023
A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)Yvonne L E Ang, Xiaotian Zhao, Thanyanan Reungwetwattana, et al.
BMC Cancer|April 16, 2020
Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancerHan Na Kang, Jae-Hwan Kim, A-Young Park, et al.
Oncotarget|February 10, 2016
Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimusSun Min Lim, Hyung Soon Park, Sangwoo Kim, et al.
Frontiers in Immunology|March 22, 2024
CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine productionKwangmin Na, Seul Lee, Dong Kwon Kim, et al.
Cancer Research|April 20, 2018
Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK InhibitorsMi Ran Yun, Sun Min Lim, Seon-Kyu Kim, et al.
Cancer Research and Treatment|December 14, 2021
Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking GroupShinkyo Yoon, Miso Kim, Yong Sang Hong, et al.
Cancer Research and Treatment|July 1, 2020
Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in KoreaSun Min Lim, Sang-We Kim, Byoung Chul Cho, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2021
Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancerBeung-Chul Ahn, Jea-Woo So, Chun-Bong Synn, et al.
Pageof 14